VolitionRX Ltd (VNRX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】VolitionRX Ltd (VNRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8209)・商品コード:DATA904C8209
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:44
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
VolitionRX Ltd (VolitionRX) is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of various conditions including colorectal cancer, prostate and lung cancers, and inflammatory and other diseases. VolitionRX also conducts research and development, and offers clinical trial services. The company has collaboration with hospital, medical center, universities and research institute. It operates in Belgium, Singapore, the UK and the US. VolitionRX is headquartered in Singapore City, Singapore.

VolitionRX Ltd (VNRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Devices Deals, 2012 to YTD 2018 10
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
VolitionRx Acquires Nucleosomics Technology Patent from Chroma Therapeutics 12
Partnerships 13
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 13
Singapore Volition to Enter into Agreement with National Taiwan University 14
VolitionRX Extends Research Agreement with University of Bonn 15
Equity Offering 16
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRx Raises USD14.1 Million in Public Offering of Shares 20
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 22
VolitionRx Completes Private Placement Of Shares For US$3 Million 24
Acquisition 25
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 25
VolitionRX Ltd – Key Competitors 26
VolitionRX Ltd – Key Employees 27
VolitionRX Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Aug 13, 2018: VolitionRx announces second quarter 2018 financial results and business update 29
May 10, 2018: VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update 31
Nov 09, 2017: VolitionRx Announces Third Quarter 2017 Financial Results and Business Update 32
Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 34
May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 35
Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 36
Corporate Communications 37
Mar 07, 2018: VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board 37
Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 38
Government and Public Interest 39
Sep 21, 2017: VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding 39
Other Significant Developments 40
May 09, 2018: VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits 40
Mar 01, 2018: VolitionRX Announces Full Fiscal Year 2017 Financial Results and Business Update 41
Mar 28, 2017: Volition America Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
VolitionRX Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Devices Deals, 2012 to YTD 2018 10
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VolitionRx Acquires Nucleosomics Technology Patent from Chroma Therapeutics 12
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 13
Singapore Volition to Enter into Agreement with National Taiwan University 14
VolitionRX Extends Research Agreement with University of Bonn 15
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRx Raises USD14.1 Million in Public Offering of Shares 20
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 22
VolitionRx Completes Private Placement Of Shares For US$3 Million 24
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 25
VolitionRX Ltd, Key Competitors 26
VolitionRX Ltd, Key Employees 27
VolitionRX Ltd, Subsidiaries 28

List of Figures
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[VolitionRX Ltd (VNRX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8209)販売に関する免責事項を必ずご確認ください。
★調査レポート[VolitionRX Ltd (VNRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆